

Life Without Limitations





ÖSSUR INVESTOR MEETING FULL YEAR 2009

4 February 2010

1





Life Without Limitations






ÖSSUR HF. JÓN SIGURÐSSON President & CEO



ÖSSUR HIGHLIGHTS FOR THE YEAR

Sales

USD 331 m



-Profitable operations EBITDA margin 20% **Operations** Healthy balance sheet EBITDA USD 67 m Strong cash flow Key milestones Second generation of Bionics **Milestones** PROPRIO FOOT[®] reimbursement further strengthening the Bionic Platform _ Changes completed in Americas B&S sales organization -Listing in Copenhagen -

AMERICAS 2009 – ENHANCED PLATFORMS





Americas 48% of total sales

- \rightarrow Overall sales declined 1%
- \rightarrow Strong prosthetics sales
- \rightarrow Challenging year in B&S
- → Structural changes of sales organization completed
- → Strengthening of sales channel through selective investments
- → Access to hospital channels through GPOs
- → US Healthcare reforms unclear

Note: All growth numbers in local currency

EMEA 2009 – MAJOR INITIATIVES ON TRACK






EMEA 48% of total sales

- \rightarrow Overall sales declined by 1%
- \rightarrow Good prosthetics sales
- \rightarrow Compression therapy declined by 5%
- → Slowdown of economy affecting especially the hospital sales in UK
- → Discontinued third party suppliers continue to affect sales while improving profitability

Note: All growth numbers in local currency

ASIA 2009 - SOLID AND STEADY GROWTH





Asia 4% of total sales


- \rightarrow Strong growth in all major markets
- \rightarrow 13% growth
- \rightarrow Good profitability

Note: All growth numbers in local currency

B&S – SIGNIFICANT PROGRESS MADE



Strong leadership, new sales structure, promising product pipeline and enhanced sales platform will support Össur in achieving its objectives in 2010



IMPORTANT PRODUCT LAUNCHES IN 2009



10 New products launched during the year



RHEO KNEE®

Redesigned and launched in 2009, the RHEO KNEE is an advanced prosthetic device that liberates its users to focus on their chosen activity, instead of having to think about how they are walking. Using sophisticated artificial intelligence, it continuously learns and adapts to an amputee's walking style and environment.

Vari-Flex[®] with FVO[™]

The well-established Vari-Flex prosthetic foot from the Flex-Foot[®] product family now incorporates Energy Vector Optimization technology (EVO) for the smoothest roll-over ever. Improved dynamic response and uncompromised stability through the gait cycle allows amputees to walk in complete comfort and confidence.



Miami Lumbar™

The Miami Lumbar is an easy-to-use spinal orthosis for post-surgical immobilization, pain relief, and the protection of injured ligaments or muscles. The superior anatomical design follows

FINANCIAL HIGHLIGHTS 2009





- Slight decline in sales
- Profitable operations
- Healthy balance sheet
- Robust cash flow



Life Without Limitations





ÖSSUR HF HJÖRLEIFUR PÁLSSON *CFO*



FINANCIAL HIGHLIGHTS Q4 2009






- Sales growth in all markets
- Increase in profits
- Excellent cash flow



Income Statements (USD '000)	Q4 2009	% of sales	Q4 2008	% of sales	Change
Net sales	87,871	100.0%	79,440	100.0%	10.6%
Gross profit	53,008	60.3%	49,011	61.7%	8.2%
	00,000	00.070	-3,011	01.770	0.270
Operating expenses (incl. other income)	-39,286	-44.7%	-38,196	-48.1%	2.9%
Profit from operations	13,722	15.6%	10,815	13.6%	26.9%
Net profit	8,074	9.2%	4,171	5.3%	93.6%
EBITDA	17,812	20.3%	16,324	20.5%	9.1%
EBITDA adjusted	17,812	20.3%	16,847	21.2%	5.7%

SALES – POSITIVE DEVELOPMENT








Growth numbers: Organic growth Q4 2009: Organic growth 3.4% LCY

GROSS PROFIT – STABLE MARGINS









OPERATING EXPENSES – MARGINAL DECLINE






NET PROFIT – IS UP






20% EBITDA Q4





CASH FLOW – IS STRONG





NET CASH PROVIDED BY OPERATING ACTIVITIES

- Increased cash conversion
- Investment in machinery
- Net cash from operations USD 23 million

BALANCE SHEETS 31 DECEMBER 2009



USD '000	31 Dec 2009	31 Dec 2008
Non current assets	448,446	463,202
Current assets	179,771	140,576
Total assets	628,217	603,778
Stockholders' equity	312,223	249,648
Non current liabilities	237,045	223,242
Current liabilities	78,949	130,888
Total equity and liabilities	628,217	603,778
Current ratio	2.3	1.1
Equity ratio	50%	41%

- Strong cash position
- Equity ratio 50%
- Net interest bearing debt / EBITDA 2.4 times
- Secured financing no covenant issues
- Debt profile to be internationalized

Net interest bearing debt / EBITDA

2.9

2.4

FINANCIAL HIGHLIGHTS Q4 2009





- Sales growth in all markets
- Increase in profits
- Excellent cash flow
- Positive outlook

2009 Guidance vs. Actual

Sales: USD 310-320 million331 millionEBITDA: USD 58-62 million67 millionEBITDA margin: 18-19%20%

Guidance 2010

Sales growth (LCY): 3 - 4% EBITDA growth: 8 - 10%



Iceross Seal-In® X5

